IXICO plc - >£2m contract extension win - Huntington’s disease

RNS Number : 3623A
29 September 2020


("IXICO" or the "Company")


>£2m contract extension win in Huntington's disease


IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, has executed a c. £2m contract to provide additional imaging services that will support a pivotal Huntington's disease (HD) study. This builds on the Company's existing contract to support our 'top-20' pharma client's Phase III study in HD.


This contract does not have significant impact on management's expectations of performance for the coming year, but will contribute to the Company's already strong order book for next year.


Giulio Cerroni, Chief Executive Officer of IXICO, commented: "We are delighted that our client has chosen to expand our partnership to support its study extension for Huntington's disease. This decision validates our technology and endorses the service provided as we help our clients throughout the trial pathway. IXICO is proud to support the development of treatments for this devastating rare disease."


For further information please contact:



+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer




Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)


Michael F Johnson / Russell Kerr (Sales)




Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or IXICO@walbrookpr.com

Paul McManus / Lianne Cawthorne /


Alice Woodings





IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.


IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.


More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Quick facts: IXICO PLC


Price: 74

Market Cap: £35.63 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Ixico set to return to double digit growth in 2022 as impact of Covid-19 on...

IXICO PLC (AIM:IXI, FRA:PYPB, OTC:PHYOF) (LON:IXI) CFO Grant Nash joins Proactive London's Katie Pilbeam about returning to double-digit revenue growth again in 2022 as the impact of Covid-19 on drug trials eases and activity picks up again. Nash explains that having enjoyed exceptional...

on 11/8/21

3 min read